newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones

Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combinatio